This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. Under the agreement,...
Hence then, the article about menarini group and insilico medicine enter a second exclusive global license agreement for an ai discovered preclinical asset targeting high unmet needs in oncology was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology )
Also on site :
- AI startup Rocket offers vibe McKinsey-style reports at a fraction of the cost
- JP Morgan Chase head warns of unexpected interest rate shocks as a result of Iran war
- This 1954 Film Ranked as Alfred Hitchcock's No. 1 'Masterpiece'